PCSK9 and acute coronary syndrome: In the recent study about proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor use for secondary prevention after acute coronary syndrome, the patients with lower LDL-C level had better outcomes about recurrent ischemic cardiovascular events during the longer follow-up period [17].